Valneva (VALN)

• Market cap: $856M
• 1 day: 12.27%
• 5 days: 10.17%
• 1 month: -17.87%
• 3 months: 69.56%
• 6 months: 42.84%
• Year to date: 111.23%
• 1 year: 64.25%
• 5 years: -64.83%
• 10 years: -64.83%
• Sector: Healthcare
• Industry: Biotechnology

About: Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Employees: 713

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

475% more capital invested

Capital invested by funds: $4.45M [Q1] → $25.6M (+$21.1M) [Q2]

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

38% more funds holding

Funds holding: 13 [Q1] → 18 (+5) [Q2]

4.9% more ownership

Funds ownership: 0.41% [Q1] → 5.31% (+4.9%) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13
• Avg. target: $15.5
• High target: $18

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Guggenheim Vamil Divan	$13	Buy Maintained	8 Sep 2025
HC Wainwright & Co. Brandon Folkes	$18	Buy Reiterated	25 Aug 2025